If you have Medicare Part D and your prescription for an FDA-approved JAK inhibitor to treat alopecia areata has been denied, we want to hear from you. In 2026, the Centers for Medicare & Medicaid Services (CMS) clarified that Medicare Part D plans should cover FDA-approved JAK inhibitors prescribed for medically accepted indications, including severe alopecia areata. While many patients are successfully obtaining coverage, others continue to report denials, delays, or other barriers to accessing treatment. Although Medicare Part D plans usually require prior authorization (meaning your doctor must submit a request to your plan to prove the treatment is necessary), eligible patients should have access to medically necessary, FDA-approved treatments. If you have experienced a denial—or have had difficulty obtaining coverage—we want to learn more about your experience. Why is NAAF collecting this information? Every patient’s story helps us better understand where barriers still exist. By collecting information from people living with alopecia areata across the country, NAAF can understand why denials are occurring, and advocate for improvements in access to treatment. Your experience helps us educate policymakers, healthcare providers, insurers, and others about the real-world challenges patients continue to face. Whether your prescription was eventually approved after an appeal or remains denied, your experience matters. Tell Us About Your Experience Complete this information form. Thank you for sharing your experience.
